Dr. Erba on the FDA Approval of CPX-351 in AML

Video

In Partnership With:

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, sheds light on the FDA approval of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, sheds light on the FDA approval of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).

One of the challenges in treatment of patients with AML is based on the biology of the disease. Many patients have AML that rose from myelodysplastic syndrome, a myeloproliferative neoplasm, or even induced by prior chemotherapy. For these patients, they are often more resistant to chemotherapy and their long-term outcomes are worse. These disease states are also more common in older patients. Therefore, developing novel therapeutic options for these populations is needed.

The FDA recently approved CPX-351, which is a fixed-combination of daunorubicin and cytarabine, for adult patients with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, based on an improvement in overall survival in a phase III study.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD